



2016 CCS/CPCA Position Statement on The Evaluation of Syncope in Children and Adolescents: Disclosure of Conflict of Interests

| Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline | | | | | | |
|---|-------------------------------|------------------------------|--|---|---------------------------------|----------------------------|
| Member | Consulting fees/ Honoraria | Clinical Trials | Officer, director, or in any other fiduciary role | Ownership/ partnership/ principal | Intellectual property rights | Other financial benefit |
| Primary Panel | | | | | | |
| Shubhayan Sanatani | Johnson & Johnson | | | | | |
| Vann Chau | | | | | | |
| Renée Blondin | | | | | | |
| Andrew Dixon | | | | | | |
| Anne Fournier | | | | | | |
| Robert Sheldon | | | Saskatchewan Health Research Foundation Board CCSA President | | | |
| Secondary Panel | | | | | | |
| Dominic Allain | | | | | | |
| Nicolas Chrestian | | | | | | |
| Robin Clegg | | | | | | |
| Alexandra Jevremovic | | | | | | |
| Andrew Krahn | | Boston Scientific, Medtronic | | | | |
| Michael Sean McMurtry | | | | | | |